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Background: It has been suggested that low diastolic
blood pressure (BP) while receiving antihypertensive treat-
ment (hereinafter called on-treatment BP) is harmful in
older patients with systolic hypertension. We examined
the association between on-treatment diastolic BP, mor-
tality, and cardiovascular events in the prospective pla-
cebo-controlled Systolic Hypertension in Europe Trial.
Methods: Elderly patients with systolic hypertension
were randomized into the double-blind first phase of the
trial, after which all patients received active study drugs
(phase 2). We assessed the relationship between out-
come and on-treatment diastolic BP by use of multivar-
iate Cox regression analysis during receipt of placebo
(phase 1) and during active treatment (phases 1 and 2).
Results: Rates of noncardiovascular mortality, cardio-
vascular mortality, and cardiovascular events were 11.1,
12.0, and 29.4, respectively, per 1000 patient-years with
active treatment (n=2358) and 11.9, 12.6, and 39.0, re-
spectively, with placebo (n=2225). Noncardiovascular
mortality, but not cardiovascular mortality, increased with
low diastolic BP with active treatment (P .005) and with
placebo (P .05); for example, hazard ratios for lower
diastolic BP, that is, 65 to 60 mm Hg, were, respectively,
1.15 (95% confidence interval, 1.00-1.31) and 1.28 (95%
confidence interval, 1.03-1.59). Low diastolic BP with ac-
tive treatment was associated with increased risk of car-
diovascular events, but only in patients with coronary
heart disease at baseline (P .02; hazard ratio for BP 65-60
mm Hg, 1.17; 95% confidence interval, 0.98-1.38).
Conclusions: These findings support the hypothesis that
antihypertensive treatment can be intensified to pre-
vent cardiovascular events when systolic BP is not un-
der control in older patients with systolic hypertension,
at least until diastolic BP reaches 55 mm Hg. However, a
prudent approach is warranted in patients with concomi-
tant coronary heart disease, in whom diastolic BP should
probably not be lowered to less than 70 mm Hg.
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T HE EXISTENCE OF A J-CURVErelationship between mor-tality or cardiovascular eventand diastolic blood pres-sure (BP) during antihyper-
tensive treatment (hereinafter called on-
treatment BP) remains a matter of debate
in patients with hypertension.1 Apart from
intervention trials, in which patients are
randomized to different target BP levels,2
placebo- or nontreatment-controlled trials
are probably the best way to evaluate the
J-curve. A large meta-analysis of indi-
vidual patient data from 7 trials3-10 showed
a higher incidence of cardiovascular death
with lower on-treatment diastolic BP, but
this relationship was also observed for non-
cardiovascular death and similar relation-
ships existed in the control patients; thus,
the worse prognosis of lower diastolic BP
could not be solely ascribed to antihyper-
tensive treatment. A more recent meta-
analysis11 involving 10 trials4-10,12-14 con-
cluded that lowering diastolic BP to less
than 70 mm Hg did not cause harm. How-
ever, these meta-analyses did not differ-
entiate between systolic-diastolic hyper-
tension and isolated systolic hypertension.
Therefore, the results may not apply to pa-
tients with systolic hypertension who may
be particularly vulnerable to low on-
treatment diastolic BP, as shown in a post
hoc analysis of the Systolic Hypertension
in the Elderly Program (SHEP), in which
a J-curve was observed for incident car-
diovascular events during active treat-
ment but not during administration of pla-
cebo.15 The SHEP investigators concluded
that it could be harmful to intensify anti-
hypertensive therapy when diastolic BP has
reached 70 mm Hg. In addition, the SHEP
analysis did not stratify for coronary heart
disease (CHD) at baseline, whereas the risk
of low on-treatment diastolic BP could be
particularly high in patients with CHD.1,16
Because of the far-reaching conse-
quences of the conclusions from the SHEP
trial, we analyzed the relationship be-
tween on-treatment diastolic BP, mortal-
ity, and cardiovascular events in older
patients with systolic hypertension ran-
domized into the Systolic Hypertension in
Europe (Syst-Eur) Trial12,17 and also ac-
counted for CHD at baseline.
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METHODS
TRIAL DESIGN
The protocol of the Syst-Eur Trial12 was approved by the ethics
committees of the University of Leuven, Leuven, Belgium, and
participating centers; all subjects in the 198 centers gave in-
formed consent. Eligible patients had to be 60 years or older. Dur-
ing the run-in period with placebo, patients were seen at 3 base-
line visits 1 month apart. Data about medical history were collected,
including history of CHD, which comprised myocardial infarc-
tion and angina pectoris, based on supporting documents and ex-
aminations available to the local investigators. At each visit, BP
was measured twice with a standard sphygmomanometer with
thepatient sitting.Patientswereadmitted to thedouble-blindphase
of the trial when they had an average run-in period systolic BP
of 160 to 219 mm Hg with diastolic BP less than 95 mm Hg.
Patients were randomized to active medication or matched
placebo groups. Active treatment consisted of nitrendipine (10-
40 mg/d), which could be combined with or replaced by enala-
pril maleate (5-20 mg/d) or hydrochlorothiazide (12.5-25 mg/d)
or both drugs, to reduce the sitting systolic BP by 20 mm Hg or
more and to less than 150 mm Hg. At each 3-month visit, BP was
measured twice with the patient sitting and the 2 BP measure-
ments were averaged. When phase 1 of the Syst-Eur Trial was
stopped on February 14, 1997, after a median follow-up of 2.0
years (range,1month to8.1years),12 patients in thecontrolgroup
were switched to the active study treatment regimen and patients
in theactive treatmentgroupcontinuedreceivingactive treatment
(phase2).17 Visitswerescheduledevery6months inthestudycen-
ters and thesame informationwascollectedasduring thedouble-
blindphaseof the trial.Theextended follow-upendedonDecem-
ber 31, 2001. In the present analyses, follow-up data in the
placebo group are from phase 1 of the trial and follow-up data in
the active treatment group are from phases 1 and 2. For patients
who withdrew from the study or who could not be followed up
as planned, investigators collected data about vital status, occur-
renceofdiseases,anduseofantihypertensivemedicationviayearly
telephone contact with patients, family members, or general
practitioners.12,17
OUTCOMES
Outcome measures were as follows: (1) fatal and nonfatal cere-
brovascular events including stroke and transient ischemic attack;
(2) fatal and nonfatal CHD events including sudden death, myo-
cardial infarction, and coronary revascularization (percutane-
ous coronary interventions and coronary artery bypass surgery);
(3) an aggregate of all cardiovascular events (cardiovascular death,
myocardial infarction, stroke, heart failure, coronary revascular-
ization, aortic aneurysm, and transient ischemic attack); (4) car-
diovascular mortality including all fatal cardiovascular events; and
(5) noncardiovascular death. Events were corroborated by the Syst-
Eur Trial End Point Committee.12,17
STATISTICAL ANALYSIS
Database management and statistical analyses were performed
using SAS software (version 8.2; SAS Institute Inc, Cary, North
Carolina). Data are reported as mean±SD or as percentage. The
prognostic value of diastolic BP during follow-up was analyzed
in patients with at least 1 follow-up visit. In the first analysis, dia-
stolic BP (linear and quadratic term) was entered as a time-
dependent covariate in multivariate Cox regression models.18 In
this analysis, the likelihood of an event that occurred at time
tdepends on the value of the last available diastolic BP before time
t for all subjects still in follow-up at time t. We adjusted for vari-
ables with potential influence on BP and outcome, that is, age,
sex, smoking status, and previous antihypertensive treatment at
baseline, and weight, stroke, myocardial infarction, and diabetes
mellitus both at baseline and as time-dependent covariates dur-
ing follow-up. The analyses were performed with and without sys-
tolic BP as a continuous time-dependent covariate. We plotted
the adjusted hazard ratio (HR) vs on-treatment diastolic BP. The
(adjusted HR−1)100 is the percent increase in risk associated
with the 5–mm Hg lower on-treatment diastolic BP. In the sec-
ond analysis, we calculated HRs in 5–mm Hg decrements of on-
treatment diastolic BP, as in the SHEP study.15 For each cutoff
value, outcome was compared between patients with diastolic BP
below that level and patients with diastolic BP at or above that
level. Adjustment was performed as described, with inclusion of
on-treatment systolic BP as a dichotomized variable (cutoff value,
140 mm Hg), as in the SHEP trial.15 These analyses were re-
peated with on-treatment systolic BP as a continuous variable and
without systolic BP. All analyses were performed on the basis of
intention to treat. A 2-tailed P .05 was considered statistically
significant.
RESULTS
PATIENT CHARACTERISTICS
AT BASELINE
Among the 4695 patients randomized in phase 1 of the
Syst-Eur Trial, 2225 patients in the placebo group and
2358 patients in the active treatment group had at least
1 follow-up visit. Patient characteristics at baseline were
not significantly different between the groups (Table1).
Mean±SD age of the total study population was 70.2±6.7
years; 66.9% were women. Mean±SD BP was 173.8±9.9/
85.5±5.8 mm Hg; 46.5% of patients had been treated with
antihypertensive drugs in the last 6 months before in-
Table 1. Patient Characteristics at Baseline in the Placebo
and Active Treatment Groupsa
Characteristic
Placebo
Group
(n = 2225)
Active
Treatment
Group
(n = 2358)
Age, y 70.1 ± 6.6 70.2 ± 6.7
Female sex 66.5 67.4
Body mass indexb 27.0 ± 4.0 27.0 ± 4.2
Blood pressure, mm Hg
Systolic 173.9 ± 10.1 173.7 ± 9.8
Diastolic 85.5 ± 5.9 85.5 ± 5.8
Pulse rate, beats/min 73.0 ± 8.1 73.2 ± 7.9
Previous antihypertensive therapy 46.7 46.3
Previous cardiovascular complicationsc 30.3 29.4
History of coronary heart diseasec 14.7 14.2
Diabetes 10.1 10.5
Current smoking 7.0 7.3
Serum creatinine, mg/dL 1.0 ± 0.2 1.0 ± 0.2
Serum cholesterol, mg/dL 236 ± 46 231 ± 46
SI conversion factors: To convert creatinine to millimoles per liter, multiply
by 88.4; cholesterol to millimoles per liter, multiply by 0.0259.
aData are given as mean ± SD or percentage.
bCalculated as weight in kilograms divided by height in meters squared.
c Includes coronary heart disease (myocardial infarction and angina pectoris),
heart failure, left ventricular hypertrophy, stroke, central nervous system.
involvement, renal involvement, retinopathy grade 3, and aortic aneurysm.
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clusion in the trial, 29.9% had previous cardiovascular
complications, and 14.5% had a history of CHD.
BP AND EVENTS DURING FOLLOW-UP
In the placebo group, 52 patients (2.3%) were lost to fol-
low-up by the end of phase 1; after longer follow-up, 284
patients (12.0%) in the active treatment group were lost
to follow-up by the end of phase 2. Lost to follow-up was
defined as no information available for more than 1 year.
At the last follow-up visit, 2070 patients in the active treat-
ment group and 1782 patients in the placebo group re-
ceived active study medication or placebo tablets; the study
medication was combined with open-label antihyperten-
sive drugs in 220 actively treated patients and 51 patients
in the placebo group. One hundred fifty-seven patients in
the active treatment group and 241 patients in the pla-
cebo group received open-label antihypertensive drugs only.
The remaining 131 patients in the active treatment group
and 202 patients in the placebo group were untreated. Mean
systolic BP, that is, the mean systolic BP of all postbaseline
results for each patient, was 149.0±10.3 mm Hg (range,116-
206 mm Hg) during active treatment and 161.8±13.6
mm Hg (range, 114-238 mm Hg) during placebo admin-
istration. These values were, respectively, 78.8±6.0 mm Hg
(range, 50-100 mm Hg) and 83.6±6.4 mm Hg (range, 50-
110 mm Hg) for diastolic BP. Table 2 gives the distribu-
tion of mean diastolic BP and of all diastolic BP measure-
ments in the 2 groups. The percentage of patients with at
least 1 diastolic BP measurement less than 55 mm Hg dur-
ing follow-up was 5.7% in the active treatment group and
1.1% in the placebo group. The rates of events per 1000
patient-years for cardiovascular events, cardiovascular mor-
tality, and noncardiovascular mortality were 39.0, 12.6, and
11.9, respectively, during 5219 patient-years of follow-up
during placebo treatment and 29.4, 12.0, and 11.1 during
14 511 patient-years during active treatment (Table 3).
PROGNOSTIC SIGNIFICANCE
OF DIASTOLIC BP: CONTINUOUS ANALYSIS
Figure 1 shows the results for cardiovascular and non-
cardiovascular mortality without inclusion of on-
treatment systolic BP in the regression models. On-
treatmentdiastolicBPdidnotaffect cardiovascularmortality,
either during active treatment or during placebo adminis-
tration. In contrast, noncardiovascular mortality was sig-
nificantly and curvilinearly associated with diastolic BP, both
with active treatment (P.005) and with placebo (P.05).
Low on-treatment diastolic BP was associated with higher
noncardiovascular mortality. For example, the HR for non-
cardiovascular mortality for 5–mm Hg lower diastolic BP,
from 65 to 60 mm Hg, was 1.15 (95% confidence interval
[CI], 1.00-1.31) with active therapy and 1.28 (95% CI, 1.03-
1.59) with placebo. Results were similar for cancer mor-
tality, for which the HRs were, respectively, 1.26 (95% CI,
1.01-1.58) and 1.36 (95% CI, 0.98-1.88).
Figure2 shows the results for cerebrovascular events
and CHD events. In the placebo group, the association
between on-treatment diastolic BP and the risk of a cere-
brovascular event was curvilinear, indicating an in-
creased risk at low diastolic BP levels (P .01); for ex-
ample, the HR for 5–mm Hg lower diastolic BP, from 65
to 60 mm Hg, was 1.25 (95% CI, 1.01-1.54). This was
not the case with active treatment. The CHD risk re-
mained unchanged at lower diastolic BP with both ac-
tive therapy and placebo. No significant association was
found between the risk of all cardiovascular events and
on-treatment diastolic BP during either active treatment
or placebo administration (data not shown).
Figure 3 shows the relationship between on-
treatment diastolic BP and the aggregate of all cardio-
vascular events according to the history of CHD at base-
line. During active treatment, there were 25.6
cardiovascular events per 1000 patient-years in the 2022
patients without CHD at baseline and 56.7 events per 1000
patient-years in the 336 patients with CHD. In the pla-
cebo group, there were 24.6 events per 1000 patient-
Table 2. Frequency Distribution of Mean Diastolic
Blood Pressure and All Diastolic Blood Pressure
Measurements During Follow-up in the Placebo
and Active Treatment Groupsa
Variable
Placebo Group
Active Treatment
Group
Mean
DBP
All
DBPs
Mean
DBP
All
DBPs
No. of BP
measurements
2225 21 122 2358 41 774
DBP category, mm Hg
95 3.4 7.0 0.4 2.1
95-85 41.6 40.4 13.9 20.1
85-75 47.2 38.6 63.7 48.0
75-65 7.3 12.0 20.3 24.0
65-55 0.4 1.7 1.5 5.0
55 0.04 0.2 0.2 0.7
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure.
aBlood pressure values are given as percentage.
Table 3. Numbers and Rates per 1000 Patient-Years
of First-Occurring Events in the Placebo
and Active Treatment Groupsa
Variable
Placebo Group
(n = 2225)
Active
Treatment Group
(n = 2358)
Patient-years of follow-up 5219 14 511
Cerebrovascular eventsb 93 (18.3) 151 (10.7)
Coronary heart disease eventsc 71 (13.8) 181 (12.7)
Cardiovascular eventsd 193 (39.0) 404 (29.4)
Mortality
Cardiovascular 66 (12.6) 174 (12.0)
Noncardiovascular 62 (11.9) 161 (11.1)
Cancer 27 (5.2) 59 (4.1)
Unknown cause 1 (0.2) 9 (0.6)
aData are given as number of events (rate per 1000 patient-years) unless
otherwise indicated.
b Includes stroke and transient ischemic attack.
c Includes sudden death, myocardial infarction, and coronary
revascularization.
d Includes cardiovascular death, myocardial infarction, coronary
revascularization, stroke, transient ischemic attack, heart failure, and aortic
aneurysm.
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years in the 1897 patients without CHD and 73.3 events
per 1000 patient-years in the 328 patients with CHD. Low
diastolic BP during active treatment was not associated
with increased risk in patients free of CHD at baseline,
whereas the risk increased when on-treatment diastolic
BP was lower than about 75 mm Hg in patients with CHD
(P .02), with an HR of about 1.1 at 70 mm Hg. How-
ever, the interaction between CHD status at baseline and
on-treatment diastolic BP was not significant (P=.19). In
the placebo group, there was no support for an influ-
ence of low diastolic BP on the incidence of cardiovas-
cular events in patients with CHD at baseline, but low
diastolic BP was associated with increased risk of car-
diovascular events in patients without CHD (P .01).
However, the interaction between CHD status at base-
line and on-treatment diastolic BP was not significant
(P=.13). Results were similar when on-treatment sys-
tolic BP was included as a continuous time-dependent
covariate in the analyses (data not shown).
PROGNOSTIC SIGNIFICANCE
OF DIASTOLIC BP: ANALYSIS BY 5–mm Hg
CUTOFF CATEGORIES
All analyses were repeated using 5–mm Hg cutoff cat-
egories for on-treatment diastolic BP, as in the SHEP trial.15
These analyses yielded results similar to those when dia-
stolic BP was used as a continuous variable. Similar to
Figure 4 in Somes et al,15 our Figure 4 shows the re-
sults for the aggregate of all cardiovascular events, with
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Figure 1. Hazard ratios for cardiovascular (A and C) and noncardiovascular mortality (B and D) in relation to on-treatment diastolic blood pressure (BP) (defined
as low BP while receiving antihypertensive treatment) in the active treatment and placebo groups, adjusted for age, sex, smoking status, and previous
antihypertensive treatment at baseline, and body weight, stroke, myocardial infarction, or diabetes at baseline and during follow-up. The hazard ratio gives the risk
associated with a 5–mm Hg lower diastolic BP.
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inclusion of on-treatment systolic BP as a dichotomized
variable in the model. There was no consistent associa-
tion between on-treatment diastolic BP and the ad-
justed HR for these events with either active treatment
or placebo. Results were similar when on-treatment sys-
tolic BP was used as a continuous variable or was re-
moved from the models (data not shown).
COMMENT
The major findings of the present study in older pa-
tients with isolated systolic hypertension are that low-
ering of diastolic BP with active antihypertensive treat-
ment, to as low as about 55 mm Hg, does not seem to
increase cardiovascular mortality, whereas low diastolic
BP is associated with higher noncardiovascular mortal-
ity. In patients with evidence of CHD at baseline, low on-
treatment diastolic BP is associated with increased risk
of cardiovascular events, which is not the case in pa-
tients without a history of CHD. Inclusion of on-
treatment systolic BP in the regression models did not
affect the relationships between on-treatment diastolic
BP and outcome, which indicates that the findings were
not confounded by the achieved systolic BP.
Many observational cohort studies reported on the
shape of the relationship between BP and risk in various
populations, including patients with hypertension re-
ceiving BP-lowering treatment.1 The results have not al-
ways been consistent. In addition, data from untreated
subjects are unlikely to be applicable to treated hyper-
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Figure 2. Hazard ratios for cerebrovascular events (A and C) and coronary heart disease (CHD) events (B and D) in relation to on-treatment diastolic blood
pressure (BP) (defined as low BP while receiving antihypertensive treatment) in the active treatment and placebo groups, adjusted for age, sex, smoking status,
and previous antihypertensive treatment at baseline, and body weight, stroke, myocardial infarction, or diabetes at baseline and during follow-up. The hazard ratio
gives the risk associated with a 5–mm Hg lower diastolic BP.
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tensive patients, and observational studies on treated hy-
pertensive patients are difficult to interpret in the ab-
sence of a control group. A recent secondary analysis of
the International Verapamil-Trandolapril Study empha-
sized the existence of a J-curve in actively treated pa-
tients with hypertension with stable CHD.16 The find-
ing of a J-curve may be the result of confounding factors
and ill health, associated with low BP and high risk for
events (reverse causation). This has been confirmed in
a large Finnish observational study in treated hyperten-
sive patients,19 in whom the observed J-curve relation-
ship between diastolic BP and cardiovascular and non-
cardiovascular mortality could be ascribed to preexisting
cardiovascular disease, resulting in low diastolic BP. Pla-
cebo- or nontreatment-controlled trials are more appro-
priate for assessment of the existence of a J-curve for on-
treatment BP because results in treated patients can be
compared with those in a control group. In a meta-
analysis of individual patient data from 7 randomized clini-
cal trials involving 40 233 persons with primarily systolic-
diastolic hypertension,4-10 a J-curve relationship was
observed between diastolic BP and the risk of cardiovas-
cular and noncardiovascular mortality in both treated and
untreated patients.3 The authors concluded that the in-
creased risk observed in patients with low BP was not
related to antihypertensive treatment and could prob-
ably be explained by poor health conditions. This con-
clusion is supported by the results from the European
Working Party on High Blood Pressure in the Elderly trial
in which patients with low on-treatment BP had lower
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Figure 3. Hazard ratios for cardiovascular events in relation to on-treatment diastolic blood pressure (BP) (defined as low BP while receiving antihypertensive
treatment) in patients without (A and C) and with (B and D) coronary heart disease (CHD) at baseline in the active treatment group and in the placebo group,
adjusted for age, sex, smoking status, and previous antihypertensive treatment at baseline, and body weight, stroke, myocardial infarction, or diabetes at baseline
and during follow-up. The hazard ratio gives the risk associated with a 5–mm Hg lower diastolic BP.
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values for body mass index and hemoglobin, which can
be considered indicators of poor health.20
When older patients with isolated systolic hyperten-
sion are treated with antihypertensive drugs, not only sys-
tolic but also diastolic BPs are reduced.8,12,17,21 It has been
argued that patients with isolated systolic hypertension
and, thus, by definition having low diastolic BP, would
be particularly vulnerable to the consequences of treat-
ment-induced further lowering of diastolic BP.1 This is
an important issue of clinical relevance because dia-
stolic BP may reach very low values in these patients be-
fore systolic BP is normalized. The SHEP investigators
concluded that lower achieved diastolic BP was associ-
ated with increased risk of CHD, stroke, and cardiovas-
cular disease in actively treated patients; thus, some pa-
tients may have been overtreated.15 The relative risk for
the combined cardiovascular events became significant
for diastolic BP less than 70 mm Hg and approached a
2-fold increase in risk for diastolic BP less than 55 mm Hg.
This adverse relationship was not observed in the
control group. Our overall results differ from those of
the SHEP trial. In the active treatment group, we have
not observed significant relationships between on-
treatment diastolic BP and, respectively, cardiovascular
mortality, cerebrovascular events, CHD events, and an
aggregate of cardiovascular events, also when applying
the same statistical methods as in the SHEP trial.15
Several differences between the SHEP trail and the
Syst-Eur Trial should be considered. The cutoff value for
diastolic BP required for randomization into the trial was
90 mm Hg in the SHEP trial and 95 mm Hg in the Syst-
Eur Trial. The SHEP trial investigators could analyze on-
treatment diastolic BP down to 25 mm Hg, whereas dia-
stolic BP was rarely less than 55 mm Hg in the Syst-Eur
Trial. First-line treatment in the SHEP trial was a di-
uretic (chlorthalidone), with the possible addition of the
-blocker atenolol or reserpine for better BP control; in
the Syst-Eur Trial, treatment was started with the dihy-
dropyridine calcium channel blocker nitrendipine, to
which the converting enzyme inhibitor enalapril and hy-
drochlorothiazide could be added. Patients with CHD at
baseline were not analyzed separately in the SHEP trail.
About 5% of the randomized patients had a history of myo-
cardial infarction8; thus, it is unlikely that the percent-
age of patients with CHD exceeded the prevalence of CHD
at baseline in the Syst-Eur Trial.
In contrast to the findings on cardiovascular mortal-
ity, we observed increases in noncardiovascular and can-
cer mortality at low diastolic BP, both with active treat-
ment and with placebo. These findings are compatible
with the notion that the J-curve may be explained by ill
health and reverse causation. These data could also sug-
gest that one should be careful in treating patients at high
risk of noncardiovascular death.
An unexpected observation in the placebo group was
that low diastolic BP was associated with a higher inci-
dence of cerebrovascular events and not of CHD. How-
ever, the former finding agrees with the pooled analysis
of 9 epidemiologic studies in patients with isolated sys-
tolic hypertension in which an inverse relationship be-
tween stroke mortality and diastolic BP was observed.22
That lower diastolic BP was not associated with in-
creased risk of cerebrovascular events during active treat-
ment in the Syst-Eur Trial is compatible with a greater
reduction in stroke risk23 and a greater decrease in ca-
rotid intima-media thickness24 with regimens based on
calcium channel blockers than with other regimens.
Some limitations of the present post hoc analysis must
be considered. All patients received active study treat-
ment after the end of the double-blind phase of the trial,
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Figure 4. Hazard ratios for cardiovascular events according to on-treatment diastolic blood pressure (BP) (defined as low BP while receiving antihypertensive
treatment) by 5–mm Hg cutoff values in the active treatment (A) and placebo (B) groups, adjusted for age, sex, smoking status, and previous antihypertensive
treatment at baseline; on-treatment systolic BP as a dichotomous variable; and body weight, stroke, myocardial infarction, or diabetes at baseline and during
follow-up.
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which increased the number of observations in the ac-
tive treatment group. The number of observations and,
consequently, the power of the statistical analyses are
smaller in the placebo group, which explains the larger
CIs. The risk of low diastolic BP could be greatest for CHD
events, particularly in patients with evidence of CHD at
baseline. Whereas we observed an increased risk for an
aggregate of cardiovascular events at low diastolic BP in
patients with evidence of CHD at baseline, a similar but
nonsignificant trend was observed for incident CHD (data
not shown), related to the small number of events and
the limited power of the analysis.
Inconclusion, these findingssupport thehypothesis that
antihypertensive treatment can be intensified for the pre-
ventionofcardiovasculareventswhensystolicBP isnotun-
der control in older patients with isolated systolic hyper-
tension, at leastuntil diastolicBPreachesabout55mmHg.
However, aprudentapproach iswarranted inpatientswith
isolated systolic hypertension and concomitant CHD, in
whom diastolic BP should probably not be lowered to less
than 70 mm Hg, when the relative risk reaches about 1.1.
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